221 related articles for article (PubMed ID: 35925047)
1. A Druggable UHRF1/DNMT1/GLI Complex Regulates Sonic Hedgehog-Dependent Tumor Growth.
Yang F; Rodriguez-Blanco J; Long J; Swiderska-Syn M; Wynn DT; Li B; Shen C; Nayak A; Ban Y; Sun X; Suter RK; McCrea HJ; Capobianco AJ; Ayad NG; Robbins DJ
Mol Cancer Res; 2022 Nov; 20(11):1598-1610. PubMed ID: 35925047
[TBL] [Abstract][Full Text] [Related]
2. STAT3 is required for Smo-dependent signaling and mediates Smo-targeted treatment resistance and tumorigenesis in Shh medulloblastoma.
Yuan L; Zhang H; Liu J; Malhotra A; Dey A; Yu B; Jella KK; McSwain LF; Schniederjan MJ; MacDonald TJ
Mol Oncol; 2022 Feb; 16(4):1009-1025. PubMed ID: 34482626
[TBL] [Abstract][Full Text] [Related]
3. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
4. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
5. The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma.
Lospinoso Severini L; Ghirga F; Bufalieri F; Quaglio D; Infante P; Di Marcotullio L
Expert Opin Ther Targets; 2020 Nov; 24(11):1159-1181. PubMed ID: 32990091
[TBL] [Abstract][Full Text] [Related]
6. Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression.
Milla LA; Arros A; Espinoza N; Remke M; Kool M; Taylor MD; Pfister SM; Wainwright BJ; Palma V
Int J Cancer; 2014 Jan; 134(1):21-31. PubMed ID: 23775842
[TBL] [Abstract][Full Text] [Related]
7. β-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells.
Miele E; Po A; Begalli F; Antonucci L; Mastronuzzi A; Marras CE; Carai A; Cucchi D; Abballe L; Besharat ZM; Catanzaro G; Infante P; Di Marcotullio L; Canettieri G; De Smaele E; Screpanti I; Locatelli F; Ferretti E
BMC Cancer; 2017 Jul; 17(1):488. PubMed ID: 28716052
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the ciliary GTPase Arl13b suppresses Sonic hedgehog overactivation and inhibits medulloblastoma formation.
Bay SN; Long AB; Caspary T
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):1570-1575. PubMed ID: 29378965
[TBL] [Abstract][Full Text] [Related]
9. Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth.
Di Magno L; Manzi D; D'Amico D; Coni S; Macone A; Infante P; Di Marcotullio L; De Smaele E; Ferretti E; Screpanti I; Agostinelli E; Gulino A; Canettieri G
Cell Cycle; 2014; 13(21):3404-13. PubMed ID: 25485584
[TBL] [Abstract][Full Text] [Related]
10. Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation.
Tan IL; Wojcinski A; Rallapalli H; Lao Z; Sanghrajka RM; Stephen D; Volkova E; Korshunov A; Remke M; Taylor MD; Turnbull DH; Joyner AL
Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3392-3397. PubMed ID: 29531057
[TBL] [Abstract][Full Text] [Related]
11. Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation-driven medulloblastoma.
Yao YL; Wang YX; Yang FC; Wang C; Mao M; Gai QJ; He J; Qin Y; Yao XX; Lan X; Zhu J; Lu HM; Zeng H; Yao XH; Bian XW; Wang Y
CNS Neurosci Ther; 2022 Jul; 28(7):1033-1044. PubMed ID: 35419951
[TBL] [Abstract][Full Text] [Related]
12. Targeted treatment for sonic hedgehog-dependent medulloblastoma.
Kieran MW
Neuro Oncol; 2014 Aug; 16(8):1037-47. PubMed ID: 24951114
[TBL] [Abstract][Full Text] [Related]
13. RNF220 is required for cerebellum development and regulates medulloblastoma progression through epigenetic modulation of Shh signaling.
Ma P; An T; Zhu L; Zhang L; Wang H; Ren B; Sun B; Zhou X; Li Y; Mao B
Development; 2020 Jun; 147(21):. PubMed ID: 32376680
[TBL] [Abstract][Full Text] [Related]
14. A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.
Rodriguez-Blanco J; Li B; Long J; Shen C; Yang F; Orton D; Collins S; Kasahara N; Ayad NG; McCrea HJ; Roussel MF; Weiss WA; Capobianco AJ; Robbins DJ
Clin Cancer Res; 2019 Feb; 25(4):1379-1388. PubMed ID: 30487124
[TBL] [Abstract][Full Text] [Related]
15. Expressions of sonic hedgehog, patched, smoothened and Gli-1 in human intestinal stromal tumors and their correlation with prognosis.
Yoshizaki A; Nakayama T; Naito S; Wen CY; Sekine I
World J Gastroenterol; 2006 Sep; 12(35):5687-91. PubMed ID: 17007023
[TBL] [Abstract][Full Text] [Related]
16. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
[TBL] [Abstract][Full Text] [Related]
18. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Kool M; Jones DT; Jäger N; Northcott PA; Pugh TJ; Hovestadt V; Piro RM; Esparza LA; Markant SL; Remke M; Milde T; Bourdeaut F; Ryzhova M; Sturm D; Pfaff E; Stark S; Hutter S; Seker-Cin H; Johann P; Bender S; Schmidt C; Rausch T; Shih D; Reimand J; Sieber L; Wittmann A; Linke L; Witt H; Weber UD; Zapatka M; König R; Beroukhim R; Bergthold G; van Sluis P; Volckmann R; Koster J; Versteeg R; Schmidt S; Wolf S; Lawerenz C; Bartholomae CC; von Kalle C; Unterberg A; Herold-Mende C; Hofer S; Kulozik AE; von Deimling A; Scheurlen W; Felsberg J; Reifenberger G; Hasselblatt M; Crawford JR; Grant GA; Jabado N; Perry A; Cowdrey C; Croul S; Zadeh G; Korbel JO; Doz F; Delattre O; Bader GD; McCabe MG; Collins VP; Kieran MW; Cho YJ; Pomeroy SL; Witt O; Brors B; Taylor MD; Schüller U; Korshunov A; Eils R; Wechsler-Reya RJ; Lichter P; Pfister SM;
Cancer Cell; 2014 Mar; 25(3):393-405. PubMed ID: 24651015
[TBL] [Abstract][Full Text] [Related]
19. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors.
Rimkus TK; Carpenter RL; Qasem S; Chan M; Lo HW
Cancers (Basel); 2016 Feb; 8(2):. PubMed ID: 26891329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
